Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung.

Nine patients with resectable pulmonary metastases of malignant melanoma were treated with surgery and transfer factor. Twelve months after thoracotomy, all were alive. After a median follow-up of 20 months, only one patient had died. Historic, other-center controls treated with surgery alone had a significantly (p less than 0.025) lower survival rate. Recurrence rates tended to be lower in the transfer factor group, but the differences were not significant. These results suggest that transfer factor may prolong survival in patients with an immunologically responsive malignancy and a small residual tumor burden.